CA3133101A1 - Therapeutic methods and compositions for treating lymphoma using 6,8-bis-benzylthio-octanoic acid - Google Patents

Therapeutic methods and compositions for treating lymphoma using 6,8-bis-benzylthio-octanoic acid Download PDF

Info

Publication number
CA3133101A1
CA3133101A1 CA3133101A CA3133101A CA3133101A1 CA 3133101 A1 CA3133101 A1 CA 3133101A1 CA 3133101 A CA3133101 A CA 3133101A CA 3133101 A CA3133101 A CA 3133101A CA 3133101 A1 CA3133101 A1 CA 3133101A1
Authority
CA
Canada
Prior art keywords
administered
benzylthio
bis
lymphoma
octanoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3133101A
Other languages
English (en)
French (fr)
Inventor
Timothy S. PARDEE
Jeffrey EDELSON
Ariela NOY
Zanetta LAMAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornerstone Pharmaceuticals Inc
Memorial Sloan Kettering Cancer Center
Wake Forest University Health Sciences
Original Assignee
Memorial Sloan Kettering Cancer Center
Wake Forest University Health Sciences
Rafael Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center, Wake Forest University Health Sciences, Rafael Pharmaceuticals Inc filed Critical Memorial Sloan Kettering Cancer Center
Publication of CA3133101A1 publication Critical patent/CA3133101A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3133101A 2019-03-19 2020-03-19 Therapeutic methods and compositions for treating lymphoma using 6,8-bis-benzylthio-octanoic acid Pending CA3133101A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962820767P 2019-03-19 2019-03-19
US62/820,767 2019-03-19
PCT/US2020/023537 WO2020191144A1 (en) 2019-03-19 2020-03-19 Therapeutic methods and compositions for treating lymphoma using 6,8-bis-benzylthio-octanoic acid

Publications (1)

Publication Number Publication Date
CA3133101A1 true CA3133101A1 (en) 2020-09-24

Family

ID=72519349

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3133101A Pending CA3133101A1 (en) 2019-03-19 2020-03-19 Therapeutic methods and compositions for treating lymphoma using 6,8-bis-benzylthio-octanoic acid

Country Status (11)

Country Link
US (1) US20220151994A1 (https=)
EP (1) EP3941453A4 (https=)
JP (1) JP2022525779A (https=)
KR (1) KR20220018959A (https=)
CN (1) CN114040758A (https=)
AU (1) AU2020240091A1 (https=)
BR (1) BR112021018138A2 (https=)
CA (1) CA3133101A1 (https=)
MX (1) MX2021011250A (https=)
TW (1) TW202102211A (https=)
WO (1) WO2020191144A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3121645A1 (en) * 2018-12-20 2020-06-25 Rafael Pharmaceuticals, Inc. Oral therapy using 6,8-bis-benzylthio-octanoic acid

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263653B2 (en) * 2007-04-18 2012-09-11 Cornerstone Pharmaceuticals, Inc. Pharmaceutical formulations containing lipoic acid derivatives

Also Published As

Publication number Publication date
KR20220018959A (ko) 2022-02-15
WO2020191144A1 (en) 2020-09-24
AU2020240091A1 (en) 2021-09-30
EP3941453A4 (en) 2022-12-28
JP2022525779A (ja) 2022-05-19
BR112021018138A2 (pt) 2021-11-16
TW202102211A (zh) 2021-01-16
MX2021011250A (es) 2022-02-11
US20220151994A1 (en) 2022-05-19
EP3941453A1 (en) 2022-01-26
CN114040758A (zh) 2022-02-11

Similar Documents

Publication Publication Date Title
RU2318517C2 (ru) Комбинация, включающая n-{5-[4-(4-метилпиперазинометил)бензоиламидо]-2-метилфенил}-4-(3-пиридил)-2-пиримидинамин и химиотерапевтический агент
CA2926771C (en) Cancer treatment with combination of plinabulin and taxane
AU2002342335A1 (en) Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
KR20190025733A (ko) 원발성 호르몬 저항성 자궁내막암 및 유방암 치료 방법 및 약학적 조성물
US20250275955A1 (en) Use of tivozanib to treat subjects with refractory cancer
CA3133101A1 (en) Therapeutic methods and compositions for treating lymphoma using 6,8-bis-benzylthio-octanoic acid
KR20180006417A (ko) 카바지탁셀 및 암 치료에 대한 그의 용도
WO2025209479A1 (en) Methods of treatment of immune thrombocytopenia using sovleplenib
US20240016805A1 (en) Therapeutic methods and compositions for treating pancreatic cancer using devimistat
Yamazaki et al. Hirohiko Shibayama, Morio Matsumoto, Hiroshi Kosugi, Kazuhiro Shibayama
AU2005246965B2 (en) Combination comprising N-{5-[4(4-methyl-piperazino-methyl)-bezoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
CA3119045A1 (en) Therapeutic methods and compositions for treating acute myeloid leukemia using devimistat
EP1704863A2 (en) Combination comprising N-5-4-(4-Methyl-Piperazino-Methyl-)Benzoyla Mido]-2-Methylphenyl -4-(3-Pyridyl)-2Phyrimidine-amine and a chemotherapeutic agent
HK1098343A (en) Combination comprising n-5-4-(4-methyl-piperazino-methyl)benzoylamido]-2-methylphenyl-4-(3-pyridyl)-2phyrimidine-amine and a chemotherapeutic agent

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250903

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251103